AU2022359282A1 - Combinations of kras g12d inhibitors with pi3ka inhibitors and related methods of treatment - Google Patents
Combinations of kras g12d inhibitors with pi3ka inhibitors and related methods of treatment Download PDFInfo
- Publication number
- AU2022359282A1 AU2022359282A1 AU2022359282A AU2022359282A AU2022359282A1 AU 2022359282 A1 AU2022359282 A1 AU 2022359282A1 AU 2022359282 A AU2022359282 A AU 2022359282A AU 2022359282 A AU2022359282 A AU 2022359282A AU 2022359282 A1 AU2022359282 A1 AU 2022359282A1
- Authority
- AU
- Australia
- Prior art keywords
- inhibitor
- kras
- pharmaceutically acceptable
- salt
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163252384P | 2021-10-05 | 2021-10-05 | |
| US63/252,384 | 2021-10-05 | ||
| PCT/US2022/045619 WO2023059594A1 (en) | 2021-10-05 | 2022-10-04 | Combinations of kras g12d inhibitors with pi3ka inhibitors and related methods of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022359282A1 true AU2022359282A1 (en) | 2024-04-11 |
Family
ID=85803703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022359282A Pending AU2022359282A1 (en) | 2021-10-05 | 2022-10-04 | Combinations of kras g12d inhibitors with pi3ka inhibitors and related methods of treatment |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240408098A1 (https=) |
| EP (1) | EP4412716A4 (https=) |
| JP (1) | JP2024537139A (https=) |
| KR (1) | KR20240073112A (https=) |
| CN (1) | CN118338904A (https=) |
| AU (1) | AU2022359282A1 (https=) |
| CA (1) | CA3233566A1 (https=) |
| IL (1) | IL311834A (https=) |
| MX (1) | MX2024004213A (https=) |
| WO (1) | WO2023059594A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250114339A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor |
| US20250114346A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| WO2025080956A1 (en) * | 2023-10-12 | 2025-04-17 | Mirati Therapeutics, Inc. | Mrtx1133 pharmaceutical compositions |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2026080796A1 (en) * | 2024-10-11 | 2026-04-16 | Mirati Therapeutics, Inc. | Mrtx1133 capsule pharmaceutical compositions |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| WO2014142660A1 (en) | 2013-03-12 | 2014-09-18 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Combinations of inhibitors of mek, egfr and erbb2 in the treatment of kras-mutant lung cancer and kras-mutant colon cancer |
| AU2019355574A1 (en) | 2018-10-05 | 2021-05-06 | Sloan-Kettering Institute For Cancer Research | PI3K inhibitors and uses thereof |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| US20240139193A1 (en) * | 2019-10-15 | 2024-05-02 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| EP4225383A4 (en) * | 2020-10-08 | 2024-12-11 | Kumquat Biosciences Inc. | MODULATORS OF CELLULAR PROLIFERATION AND THEIR USES |
-
2022
- 2022-10-04 IL IL311834A patent/IL311834A/en unknown
- 2022-10-04 WO PCT/US2022/045619 patent/WO2023059594A1/en not_active Ceased
- 2022-10-04 JP JP2024520707A patent/JP2024537139A/ja active Pending
- 2022-10-04 CA CA3233566A patent/CA3233566A1/en active Pending
- 2022-10-04 CN CN202280077624.6A patent/CN118338904A/zh active Pending
- 2022-10-04 MX MX2024004213A patent/MX2024004213A/es unknown
- 2022-10-04 AU AU2022359282A patent/AU2022359282A1/en active Pending
- 2022-10-04 KR KR1020247014947A patent/KR20240073112A/ko active Pending
- 2022-10-04 EP EP22879172.9A patent/EP4412716A4/en active Pending
- 2022-10-04 US US18/694,848 patent/US20240408098A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240073112A (ko) | 2024-05-24 |
| CA3233566A1 (en) | 2023-04-13 |
| US20240408098A1 (en) | 2024-12-12 |
| IL311834A (en) | 2024-05-01 |
| EP4412716A1 (en) | 2024-08-14 |
| WO2023059594A1 (en) | 2023-04-13 |
| EP4412716A4 (en) | 2025-08-13 |
| JP2024537139A (ja) | 2024-10-10 |
| MX2024004213A (es) | 2024-07-29 |
| CN118338904A (zh) | 2024-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240408098A1 (en) | COMBINATIONS OF KRAS G12D INHIBITORS WITH PI3Ka INHIBITORS AND RELATED METHODS OF TREATMENT | |
| EP3849537B1 (en) | Combination therapies | |
| US20260097038A1 (en) | COMPOSITIONS OF ADAGRASIB AND mTOR INHIBITORS AND METHODS OF TREATMENT THEREWITH | |
| US12208099B2 (en) | Combination therapies | |
| EP4412718A1 (en) | Combination therapies of kras g12d inhibitors with sos1 inhibitors | |
| US20240423984A1 (en) | Combination therapies of kras g12d inhibitors with shp-2 inhibitors | |
| EP4552631A2 (en) | Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer | |
| US12280055B2 (en) | Combination therapies | |
| WO2023059600A1 (en) | Combinations of kras g12d inhibitors with irinotecan and related methods of treatment | |
| US20250177410A1 (en) | Combination therapies comprising a sos1 inhibitor and an egfr inhibitor | |
| US20250186453A1 (en) | Combination therapies comprising a sos1 inhibitor and a mek inhibitor | |
| HK40108895A (zh) | Kras g12d抑制剂与pi3ka抑制剂的组合及相关治疗方法 | |
| TW202428280A (zh) | 組合療法 |